Brian Lawler Articles
RSS FeedLast 50 articles...
- Moody's Gets Moody With Drugmakers
- Novo Nordisk Takes On All Comers
- No Approval for You ... Yet
- A Top BioMarin Drug Heads Overseas
- InterMune Previews a Coming Attraction
- Less Is More for Vertex
- Eli Lilly's Dose of Disclosure
- One Share Offering Too Many for Vertex?
- Bristol-Myers Puts Icahn and ImClone to the Test
- Sanofi Gets the Golden Ring
- Will Generic Biologics Get Special Treatment?
- Why Bristol-Myers Won't Pull Its ImClone Bid
- FDA Tells Gilead to Take 1 More Step
- Busy Day for MannKind
- CV Therapeutics Expands Ranexa's Reach
- Pfizer Puts Safety First
- A New Wrinkle for an Old Drug
- King's Unstoppable Urge to Merge
- ImClone and Bristol-Myers' Unfinished Business
- Will a Change Cure Sanofi?
- A Pfizer Drug With a Cloudy Future
- Why Pfizer Made an Interesting Blockbuster Bet
- Sitting Tight in September
- Will Biopharma Acquisitions Never Cease?
- Cell Genesys Takes a Body Blow
- FDA Changes Course for Elan and Biogen Idec
- King Triples Down
- Amgen Gets Its FDA Response
- Be Careful With Pay-for-Analyst Research
- Regeneron's Results Clearing Up
- PDL BioPharma's Partnership Makes Sense
- Telaprevir Tests Its Luck
- When Breaking Up Isn't Hard to Do
- A Potentially Painless PDUFA Date
- Genentech Asks Roche to Pay Up
- Dilution Lurks at AOB
- The FDA Stands Up Cardiome
- Flamel Tries to Get It in Gear
- Not Bad, Novo Nordisk
- Exelixis Gets Ready to Partner Up
- BioMarin's New Drugs Mostly Hit Their Targets
- An ImClone Deal Will Get Done
- Vertex on the Verge of Victory
- Is $60 a Share Enough for ImClone?
- Holy Moley, CV Therapeutics!
- Elan Becomes a Bad News Buy
- Examining Elan's Ups and Downs
- Amgen's Bone-Building Boost
- Glaxo Changes Course
- Place Your Biotech Bets
Fool UK
